Phase I Clinical Trial on the Tolerability and Pharmacokinetics of Recombinant Humanized Anti-PD-L1 Monoclonal Antibody MSB2311 Injection in the Treatment of Patients With Advanced Solid Tumors

This is a first-in-human (FIH), open-label, Phase 1 dose-Escalation Study of MSB2311, a humanized anti-PD-L1 monoclonal antibody, in subjects with advanced solid tumors. Qualified subjects will be enrolled to receive their assigned dose regimen of MSB2311 until disease progression or intolerable toxicity, withdrawal of consent, or end of study, whichever occurs first. The maximum treatment duration is 2 years. During the study, subjects will be evaluated for safety and toxicity, PK/PD, immunogenicity and anti-tumor activity of MSB2311.

Start Date13 Aug 2018

Sponsor / Collaborator

Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.

CTR20180925 / RecruitingPhase 1

重组人源化抗PD-L1单克隆抗体MSB2311注射液治疗晚期实体瘤患者耐受性及药代动力学I期临床试验

[Translation] Phase I clinical trial on the tolerability and pharmacokinetics of recombinant humanized anti-PD-L1 monoclonal antibody MSB2311 injection in patients with advanced solid tumors

Ia期为剂量递增阶段，主要评估安全性、耐受性，并确定MTD和RP2D。1b期为剂量扩展期，选择多种特定类型的晚期实体瘤包括淋巴瘤患者入组扩展队列，初步评价MSB2311注射液的抗肿瘤疗效，并进一步评估MSB2311注射液的安全性、耐受性、PK，和免疫原性，以及进一步探索药效学特征等

[Translation]

Phase Ia is a dose escalation phase, which mainly evaluates safety and tolerability and determines the MTD and RP2D. Phase 1b is a dose expansion phase, which selects patients with various specific types of advanced solid tumors, including lymphoma, to enroll in the expansion cohort to preliminarily evaluate the anti-tumor efficacy of MSB2311 injection, and further evaluate the safety, tolerability, PK, and immunogenicity of MSB2311 injection, as well as further explore the pharmacodynamic characteristics, etc.

Start Date13 Aug 2018

Sponsor / Collaborator

Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.

NCT03463473 / CompletedPhase 1

First-in-human, Open-label, Phase 1 Dose-Escalation Study of MSB2311, A Humanized Anti-PD-L1 Monoclonal Antibody in Subjects With Advanced Solid Tumors

This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.

Start Date12 Apr 2018

Sponsor / Collaborator

Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with MSB-2311

100 Translational Medicine associated with MSB-2311

100 Patents (Medical) associated with MSB-2311

Literatures (Medical) associated with MSB-2311

01 Aug 2023·Cancer immunology, immunotherapy : CII

Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.

Article

Author: Shi, Michael ; Li, Jing ; Qian, Xueming ; Qi, Chuan ; Zhong, Haijun ; Zhang, Jian ; Gong, Jifang ; Hu, Xichun ; Wang, Jianming ; Shen, Lin ; Zhang, Qingyuan ; Li, Jian ; Yang, Lei ; Lu, Lingmin ; Yao, Zhenling ; Zhang, Qi ; Ji, Dongmei ; Yuan, Ying

MSB2311 is a novel pH-dependent humanized anti-programmed death-ligand 1 (PD-L1) monoclonal antibody. This phase I study primarily aimed to determine the maximum tolerated dose (MTD)/recommended phase 2 dose level (RP2D) of MSB2311 in patients with advanced solid tumors or lymphoma. MSB2311 was intravenously administered at 3, 10, and 20 mg/kg every 3 weeks (Q3W) and 10 mg/kg every 2 weeks (Q2W) using 3 + 3 design. During expansion phase, eligible patients with either PD-L1 overexpression, Epstein-Barr Virus positive, microsatellite instability high/mismatch repair deficient, or high tumor mutation burden tumors were treated at RP2D. A total of 37 Chinese patients were treated, including 31 with solid tumors and 6 lymphoma. No dose limiting toxicity was reported and MTD was not reached. The trial was expanded at 20 mg/kg Q3W or 10 mg/kg Q2W, both of which were determined as RP2D. Most common drug-related treatment-emergent adverse events were anemia (43.2%), aspartate aminotransferase increase (27.0%), proteinuria (21.6%), alanine aminotransferase increase and hypothyroidism (18.9% each), thyroid stimulating hormone increased and hyperglycemia (16.2% each). Out of 20 efficacy evaluable patients with biomarker positive solid tumors, 6 achieved confirmed partial response with the median duration of response of 11.0 months (95% CI 7.0-11.4) and 4 had stable disease, resulting an objective response rate of 30.0% (95% CI 11.9, 54.3) and disease control rate of 50.0% (95% CI 27.2, 72.8). One partial response was also observed among 6 patients with lymphoma. MSB2311 demonstrated a manageable safety profile and promising antitumor activity in patients with advanced solid tumors and lymphomas.

100 Deals associated with MSB-2311

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 2	CN	Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.	-
Advanced Malignant Solid Neoplasm	Phase 1	US	Suzhou Chuangsheng Pharmaceutical Group Co., Ltd.	12 Apr 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04272944 (ASCO2021)	Phase 1	Hematologic Neoplasms \| HR-positive/HER2-low Solid Tumors	33	MSB2311 10mg/kg Q2W	(frimslujtd) = the most common AEs (>20%) included: anemia acpzjnumnz (qkmdvgrabk ) View more	Positive	28 May 2021
NCT04272944 (ASCO2021)	Phase 1	Hematologic Neoplasms \| HR-positive/HER2-low Solid Tumors	33	MSB2311 20mg/kg Q3W		Positive	28 May 2021
ASCO2020	Phase 1	HR-positive/HER2-low Solid Tumors \| Hematologic Neoplasms	27	MSB2311 20mg/kg	(dvgbyfowvy) = lqlvthbfqz nsfakvhldc (uovxyvknaj ) View more	Positive	25 May 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

MSB-2311

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation